Quinidine gluconate Rx
Generic Name and Formulations:
Quinidine gluconate 324mg; ext-rel tabs.
Various generic manufacturers
Indications for Quinidine gluconate:
Atrial and ventricular arrhythmias (see literature).
Take with fluid and in an upright position. Individualize. Prevention of premature atrial, nodal and ventricular contractions: 324–648mg every 8–12 hrs. Maintenance of sinus rhythm following cardioversion: 648mg every 12 hrs or 486–648mg every 8 hrs.
Complete AV or bundle branch block or other severe intraventricular conduction defects. Myasthenia gravis. Digitalis intoxication. Aberrant impulses, abnormal rhythms due to escape mechanisms.
Atrial flutter; digitalize first. Incomplete AV block. Heart failure. Marginally compensated cardiovascular disease. Hypotension. Renal and hepatic dysfunction. Monitor blood, liver and kidney function in long-term use. Monitor ECG and serum levels if dose is over 2.5g/day. Pregnancy (Cat.C). Nursing mothers.
Quinidine toxicity increased by amiodarone, cimetidine, ranitidine, diuretics, carbonic anhydrase inhibitors, sodium bicarbonate, verapamil, diltiazem. Potentiates anticoagulants, anticholinergics, neuromuscular blocking agents, phenothiazines, reserpine, timolol. Increases digitalis serum levels. Quinidine levels decreased by barbiturates, hydantoins, rifampin, nifedipine.
Class I antiarrhythmic.
Nausea, vomiting, abdominal pain, diarrhea, new or exacerbated arrhythmias, heart block, syncope, cinchonism, headache, blood dyscrasias, hypotension, flushing, allergic reactions, impaired hearing and vision, hepatic dysfunction.
Formerly known under the brand names Duraquin, Quinact, Quinaglute.
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies